OMedLive

CME Presentations

Myeloproliferative Disorders


Presentations


Speakers

  • David Steensma, MD

    David Steensma, MD

    David Steensma, MD

    Associate Professor of Medicine

    David P. Steensma, MD, FACP, is an associate professor of medicine at Harvard Medical School, consulting physician at Brigham & Women’s Hospital, and a faculty member in the Division of Hematological Malignancies at Dana-Farber Cancer Institute in Boston, Massachusetts. He earned his MD from the University of Chicago’s Pritzker School of Medicine, and completed an internal medicine internship and residency and a combined hematology-oncology fellowship at the Mayo Graduate School of Medicine in Rochester, Minnesota. Dr Steensma’s primary clinical and research focus is myelodysplastic syndromes, and he maintains an active interest in marrow failure syndromes. He has more than 300 publications in peer-reviewed journals that include the New England Journal of Medicine, Blood, and Leukemia.
  • Gabriela Hobbs, MD

    Gabriela Hobbs, MD

    Gabriela Hobbs, MD

    Instructor in Medicine

    Gabriela S. Hobbs, MD, is an assistant in medicine at Massachusetts General Hospital (MGH) and an instructor of medicine at Harvard Medical School, both in Boston. She earned her medical degree from Mount Sinai School of Medicine in New York, completed an internal medicine residency at Brigham and Women’s Hospital in Boston, and completed a fellowship in hematology and oncology at Memorial Sloan Kettering Cancer Center in New York. Dr. Hobbs joined the faculty at MGH in 2014, where she established a myeloproliferative neoplasms (MPNs) clinic. Her goal as a clinician and investigator is to create a comprehensive MPN clinic and research program, with research focusing on conducting clinical trials for patients with MPNs.

CME Information

Updates in Chronic Phase Chronic Myeloid Leukemia

 
  
 

ACKNOWLEDGEMENT This activity is supported by an independent educational grant from Incyte Corporation.

TUITION Complimentary

ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS Live Activity The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Enduring Material The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION Live Activity Tuesday, October 27, 2016 from 9:00 – 10:00AM ET Enduring Material The enduring material will be available from October 27, 2016 to October 27, 2017

LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to:

Implement evidence-based recommendations for molecular profiling, monitoring of treatment response, and managing tyrosine kinase inhibitor resistance.
Employ new data on the safety and efficacy of current and emerging agents and combinations, mechanisms of action, molecular targets, and routes of administration to improve CML patient outcomes.
 

TARGET AUDIENCE This activity is intended for US-based hematologists, medical oncologists, oncology nurses, pharmacists, and other clinicians involved in the diagnosis and treatment of chronic myeloid leukemia (CML) and myeloproliferative neoplasms.

ESTIMATED TIME TO COMPLETE This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION There are no fees to participate in this activity. To participate in the activity, go to www.omedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
David Steensma, MD

Consultant: Celgene, Janssen, Novartis, Takeda

 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Anne Roc, PhD Senior Medical Director PlatformQ Health Education, LLC None

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Shaina Druy, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable): This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.

Addressing the Challenges in Myeloproliferative Neoplasms

 
  
 

ACKNOWLEDGEMENT This activity is supported by an independent educational grant from Incyte Corporation.

TUITION Complimentary

ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS Live Activity The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Enduring Material The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION Live Activity Tuesday, October 27, 2016 from 10:00 – 11:00AM ET Enduring Material The enduring material will be available from October 27, 2016 to October 27, 2017

LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to:

Review the pathophysiology and common characteristics of primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.
Evaluate new data on the safety and efficacy of current and emerging agents, mechanisms of action, molecular targets, and routes of administration and utilize guidelines regarding management of myeloproliferative neoplasms.
 

TARGET AUDIENCE This activity is intended for US-based hematologists, medical oncologists, oncology nurses, pharmacists, and other clinicians involved in the diagnosis and treatment of chronic myeloid leukemia (CML) and myeloproliferative neoplasms.

ESTIMATED TIME TO COMPLETE This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION There are no fees to participate in this activity. To participate in the activity, go to www.omedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Gabriela Hobbs, MD

Consultant: Agios, Incyte

 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Anne Roc, PhD Senior Medical Director PlatformQ Health Education, LLC None

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Shaina Druy, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable): This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.